Will New Sacubitril-Valsartan and Dapagliflozin Registrations Move HF Optimization Earlier in Outpatient Care?

Which stable heart failure patients can start an SGLT2 inhibitor safely in outpatient practice?

Start an SGLT2 inhibitor in clinically stable ambulatory heart failure today if the patient is euvolemic, not hypotensive, able to take oral medications, and has no major renal/genitourinary contraindication. In Philippine outpatient guidance, adult patients with stable chronic HFrEF should receive an SGLT2 inhibitor a

Why is a 36-hour washout required when switching from an ACE inhibitor to sacubitril/valsartan?

This is a safety-critical drug-switching issue. The 36-hour washout is required to reduce the risk of potentially life-threatening angioedema when changing from an ACE inhibitor to sacubitril/valsartan. Philippine Heart Association formulary guidance explicitly states that sacubitril/valsartan must not be administered

How can low-dose quadruple therapy be established quickly in HFrEF with borderline blood pressure?

In HFrEF with borderline blood pressure, the practical goal is usually to establish all 4 foundational classes early at low dose rather than to fully up-titrate 1–2 agents first: ARNI/ACEi/ARB, evidence-based beta-blocker, MRA, and SGLT2 inhibitor. Contemporary HF guidance supports rapid sequencing because the mortalit

When should a mild early eGFR dip after dapagliflozin be observed rather than labelled intolerance?

A small, early fall in eGFR after starting dapagliflozin is usually an expected hemodynamic effect, not intolerance, if the patient is clinically well, the creatinine rise is limited, and renal function stabilizes on repeat testing. Product information and renal-protective trial data support ongoing use in appropriate

Which clinic metrics best show whether broader drug availability is improving heart failure care?

If the question is whether broader drug availability is actually improving heart failure (HF) care in clinic practice, the most informative metrics are a mix of process, access, and patient outcome measures. For outpatient HF, the clinically meaningful outcomes highlighted in Philippine HF guidance include cardiovascul